01 January 2008
Clinical immunosuppression – current status
M. KlingerAnn Transplant 2008; 13(1): 11-11 :: ID: 880166
Abstract
The current immunosuppressive regimens allow to achieve the excellent one year organ survival, exceeding in renal transplantation 90%, with acute rejection rate below 15%. However, this medal has the reverse side, and it is price to pay. 54% of the kidney allograft is lost due to the recipient death with the functioning graft, mainly due to cardiovascular diseases, infection and malignancy. 40% of the graft failure is caused by chronic allograft injury (CAI) which encompasses calcineurin inhibitor nephrotoxicity, chronic rejection, and toxicity occurring simultaneously with inadequate, not controlling alloresponse immunosuppression. The present strategies of initial post transplantation immunosuppressive treatment are diversified based on the evaluation of the recipient immunologic risk and of the delayed graft function occurrence threat. For low immunologic risk recipients, calcineurin inhibitor containing regimen; with or without anti CD25 antibody are recommended. High immunologic risk recipients are treated by polyclonal anti T-cell antibodies, with subsequent calcineurin inhibitor introduction. The polyclonal anti T-cell antibodies are also administrated in the delayed graft function appearance or when expectation for it's appearance is high. The main long-term goal in the post transplantation immunosuppressive treatment is to achieve the balance between efficacy and toxicity of the immunosuppressive regimen, with the reduction of the overall side effect "load" on patients. For that purpose two general approach are applied: corticosteroid withdrawal and avoidance protocols, and calcineurin inhibitor withdrawal/minimization protocols.
Keywords: Transplantation, Cardiovascular Diseases, nephrotoxicity
In Press
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860